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reports,  hTERT mutations were more frequent in older pa-
tients (p < 0.0001), being found only in 5 patients <20 years 
of age. In addition,  hTERT- mutated tumors were more fre-
quently recurrent (p = 0.026) and  hTERT mutations were sig-
nificantly enriched in tumors located in the right cerebellar 
hemisphere (p = 0.039). No mutations were found on the 
 H3F3A or  HIST1H3B  genes.  hTERT promoter mutations are 
frequent in medulloblastoma and are associated with older 
patients, prone to recurrence and located in the right cere-
bellar hemisphere. On the other hand, histone 3 mutations 
do not seem to be present in medulloblastoma. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Shortening of telomeres is a natural mechanism that 
occurs during the replication of somatic cells, and is re-
sponsible for cell aging and replicative senescence  [1, 2] . 
One major mechanism of telomere length control is as-
sociated with the activity of the telomerase enzyme  [1, 2] . 
The catalytic subunit of this enzyme is encoded by the 
telomerase reverse transcriptase  (hTERT) gene and mod-
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 Abstract 
 Hotspot activating mutations of the telomerase reverse tran-
scriptase (hTERT) promoter region were recently described 
in several tumor types. These mutations lead to enhanced 
expression of telomerase, being responsible for telomere 
maintenance and allowing continuous cell division. Addi-
tionally, there are alternative telomere maintenance mecha-
nisms, associated with histone H3 mutations, responsible for 
disrupting the histone code and affecting the regulation of 
transcription. Here, we investigated the clinical relevance of 
these mechanistically related molecules in medulloblasto-
ma. Sixty-nine medulloblastomas, formalin fixed and paraf-
fin embedded, from a cohort of patients aged 1.5–70 years, 
were used to investigate the hotspot mutations of the  hTERT 
promoter region, i.e.  H3F3A and  HIST1H3B , using Sanger se-
quencing. We successfully sequenced  hTERT in all 69 medul-
loblastoma samples and identified a total of 19 mutated cas-
es (27.5%). c.-124:G>A and c.-146:G>A mutations were de-
tected, respectively, in 16 and 3 samples. Similar to previous 
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ulates telomerase activity  [2, 3] . Although telomerase is 
normally silenced in somatic cells, it is active in male 
germ cells, activated lymphocytes, stem cell populations 
and during development  [4–6] . In the large majority of 
human cancers, abnormal telomerase reactivation is ob-
served, leading to telomere maintenance and limitless 
proliferative potential  [7–9] .
 Hotspot activating mutations were recently described 
in the  hTERT promoter region in a variety tumor types, 
including medulloblastomas (20%) and glioblastomas 
(83%) among many others  [10–12] . These mutations are 
located in 2 positions, c.-124:G>A and c.-146:G>A, and 
are thought to be the main biological mechanism respon-
sible for telomerase overexpression  [13, 14] . The func-
tional consequence of the presence of promoter muta-
tions was initially associated with the creation a new 
binding motif for E-twenty-six (ETS) transcription fac-
tors and ternary complex factors (TCFs) near the tran-
scription start, leading to an increased transcription of 
the  hTERT promoter of at least 2-fold, as assessed by re-
porter assays  [13, 14] . Recently, it was also demonstrated 
that the occurrence of these mutations leads to the re-
cruitment of the GABP transcription factor, and the acti-
vation of transcription and aberrant expression of  hTERT 
in several cancers  [15] . In addition to these mutations, a 
common functional single nucleotide polymorphism 
(SNP), rs2853669, located in the  hTERT promoter has 
been shown to influence the prognostic value of the mu-
tations mentioned in gliomas and bladder and renal cell 
carcinomas  [16] .
 Alternative lengthening of telomeres (ALT) pathways 
has also been described, being present in 15% of cancers. 
Inactivating  ATRX mutations, associated with histone H3 
mutations, were described in tumors with ALT pheno-
type, including 1.5% of medulloblastoma  [17] . These mu-
tations were reported to be responsible for disrupting the 
histone code and affecting the regulation of transcription 
 [18] . Mutations in histone 3 ( H3F3A , encoding H3.3 and 
 HIST1H3B , encoding H3.1) have been reported in higher 
frequencies in pediatric gliomas of different histologies, 
but have not been extensively studied in medulloblasto-
ma  [18–20] .
 In this work, we investigated the clinical relevance of 
these important regulators in medulloblastoma, confirm-
ing that  hTERT promoter mutations are a frequent event 
in medulloblastoma. These mutations were associated 
with older age, tumor recurrence and tumors from the 
right cerebellar hemisphere. On the other hand, histone 
mutations do not seem to be present in this type of brain 
tumor.
 Material and Methods 
 Tumor Samples and DNA Isolation 
 Formalin-fixed, paraffin-embedded (FFPE) medulloblastoma 
samples from 68 patients, i.e. 68 primary tumors and 1 recurrence 
(with a matched primary tumor sample) aged 1.5–70 years, were 
obtained after approval by local and multicenter ethical review 
committees at the Laboratory of Neuropathology, Hospital of San-
ta Maria (CHLN), Lisbon, Portugal, and the Federal University of 
São Paulo, São Paulo, and Barretos Cancer Hospital, Barretos, Bra-
zil. All the samples enrolled in the study were unlinked and un-
identified from their donors. Due the retrospective nature of the 
study, no written informed consent from patients was obtained. 
The presence of tumor tissue in the samples and the tumor histol-
ogy was verified on an H&E-stained section by the pathologists 
J.N.S., J.P. and G.C.A. 
 DNA was isolated using the QIAamp DNA mini kit (Qiagen) 
according to the manufacturer’s instructions and as previously re-
ported  [21] . 
 Mutation Analysis 
 hTERT promoter mutations were screened using the primers 
previously described  [22] that amplify the sites of the c.-124:G>A 
and c.-146:G>A mutations, as previously described  [12, 23, 24] . 
 Histone 3 hotspot regions previously identified  [18, 19] were 
amplified with the following primers:  H3F3A (forward: 5 ′ -CAT-
GGCTCGTACAAAGCAGA; reverse: 5 ′ -CAAGAGAGACTTTG-
TCCCATTTTT) and  HIST1H3B (forward: 5 ′ -TT TC CT TT CC-
TCCACAGACG; reverse: 5 ′ -CGGTAACGGTGAGGCTTTT).
 Amplification of PCR products was confirmed by gel electro-
phoresis. Subsequently, samples were Sanger-sequenced after PCR 
product purification with ExoStar (Invitrogen). Sequencing PCR 
was performed using the ABI PRISM 3730xL DNA analyzer (Ap-
plied Biosystems, USA) by STAB VIDA services (Portugal).
 Statistical Analysis 
 All statistical tests were done in SPSS v20.0 (SPSS Inc.). Cor-
relations between categorical values were done using the 2-tailed 
χ 2 test and the Fisher exact test. Continuous variables were assessed 
using the Mann-Whitney U test. Associations between  hTERT 
mutational status and patients’ overall survival were analyzed us-
ing the Kaplan-Meier method and the log-rank test. A p value of 
<0.05 was considered significant.
 Results 
 hTERT Is Frequently Mutated in Medulloblastoma 
 We successfully sequenced  hTERT in 69 FFPE medul-
loblastomas, corresponding to 68 primary tumors and 1 
recurrence. Of these, 35 samples were from pediatric pa-
tients (1.5–17 years of age) and 32 from adults (>18 years); 
for an additional sample we could not confirm the age at 
diagnosis. We identified a total of 19 cases (27.5%) with 
 hTERT promoter mutations ( table  1 ). The c.-124:G>A 
mutation was detected in 16 samples, and the c.-146:G>A 
mutation ( fig. 1 ) in 3 cases. 
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 Similarly to previous reports  [10, 11] ,  hTERT muta-
tions were more frequent in older patients ( table 2 ; p < 
0.0001), being found in only 3 patients younger than 17 
years (3/35, 8.6%), whereas >50% of the adult patients 
presented with  hTERT promoter mutations (18/32, 
56.3%). In addition,  hTERT- mutated tumors were more 
frequently in the recurrent cases (p = 0.026), and  hTERT 
mutations were significantly enriched in the tumors lo-
cated in the right cerebellar hemisphere (p = 0.039). No 
other clinicopathological features were found to be statis-
tically significant ( table 2 ; p > 0.05). 
 The polymorphism rs2853669 was successfully se-
quenced in 41 of the 69 samples, and was present in 41.5% 
of the cases. Although this polymorphism has been de-
scribed as modifying the survival of mutant carriers  [16] , 
we could not confirm these results in our cohort as only 6 
samples presenting the variant also had survival data. No 
differences were seen between wild-type (WT) and mu-
tated samples regarding overall survival ( fig. 2 ; p = 0.200). 
 Histone Mutations Are Rare Events in 
Medulloblastoma 
 We designed primers for the hotspot regions of  H3F3A 
and  HIST1H3B and successfully sequenced 59 samples 
for  HIST1H3B and 65 for  H3F3A . None of the samples 
analyzed harbored any mutation on  H3F3A or  HIST1H3B .
Sample
No.
Gender/
age,
years
Histology OS, m hTERT
mutation
SNP
rs2853669
H3.1 H3.3
M1 M/11 classic – WT AA WT WT
M3a M/35 classic – c.-124:GA AG WT WT
M5 M/1.5 classic – WT AG – WT
M7 F/70 classic – c.-124:GA AA WT WT
M8 M/20 classic – c.-124:GA – WT WT
M9 F/26 classic – WT – WT WT
M12 F/1.5 classic – WT – WT WT
M13 M/21 desmoplastic – WT – WT WT
M14 M/11 classic – WT AA WT WT
M15 M/28 classic – c.-124:GA AA WT WT
M16 M/34 classic – c.-124:GA AA WT WT
M17 M/6 classic – WT – WT WT
M18 F/24 classic – c.-124:GA AA WT WT
M19 F/34 classic – WT AA WT WT
M20 M/12 classic WT – WT WT
M22 F/16 classic – WT – – WT
M24 M/7 classic – WT – WT WT
M25 M/35 classic – WT AG WT WT
M26 M/2 classic – WT – WT WT
M27 M/65 classic – WT AA WT WT
M28 M/39 classic – c.-124:GA AG WT WT
M29 F/8 classic – WT GG WT WT
M30 F/26 classic – c.-146:GA AA WT WT
M31 F/2 classic – WT AA WT WT
M32 M/33 classic – c.-124:GA GG WT WT
M33 M/4 classic – WT AA WT WT
M34 F/9 classic – WT AA WT WT
M35 M/13 classic – WT – WT WT
M36 F/18 desmoplastic – c.-124:GA AG WT WT
M41 M/11 classic 24 WT – WT WT
M42 F/7 classic 88 WT – WT WT
M43 F/18 desmoplastic 4 WT – WT WT
M45 M/27 classic 24 WT – WT WT
M46 F/24 classic 42 WT AA WT WT
Sample
No.
Gender/
age,
years
Histology OS, m hTERT
mutation
SNP
rs2853669
H3.1 H3.3
M47 F/10 classic 109 WT – – WT
M48 M/12 desmoplastic 101 c.-124:AA – WT WT
M49 M/18 classic 42 c.-124:GA – WT WT
M52 M/19 classic 94 WT – – WT
M54 M/7 classic 68 WT – WT WT
M55 F/19 desmoplastic 66 c.-124:GA AG WT WT
M58 M/2 nodular 47 WT AA WT WT
M61 M/8 classic 73 WT AA WT WT
M62 M/8 classic 20 WT AA WT WT
M66 M/16 classic 30 WT AA WT WT
M67 M/2 desmoplastic 2 WT AA WT WT
M68 M/5 classic 44 WT AA WT WT
M69 M/4 nodular 44 WT AA WT –
M70 F/17 classic 42 WT AG WT WT
M74 M/18 desmoplastic 114 c.-146:AA – WT WT
M75 F/21 classic 48 c.-124:GA AG WT WT
M76 F/20 classic 1 WT AA WT WT
M77 M/26 desmoplastic 16 c.-124:GA AA WT WT
M78 F/4 classic 8 WT AG WT WT
M79 F/9 classic 10 WT AG WT WT
M81 M/28 desmoplastic 72 c.-124:GA AG WT WT
M82 F/10 classic 104 WT AA WT WT
M84 – desmoplastic – WT – – WT
M86 M/38 classic – WT – – –
M87 M/39 classic – c.-146:GA – – –
M91 M/15 classic – WT – WT WT
M95 M/24 classic – WT AA WT WT
M96 M/35 classic – c.-124:GA – – WT
M98 M/35 – – WT – – –
M100 M/6 classic – WT – – WT
M107 M/9 classic – WT – WT WT
M111 M/33 desmoplastic – WT GG WT WT
M119 –/28 desmoplastic – WT GG WT WT
M122 M/28 desmoplastic – WT AG WT WT
 Table 1.  Clinicopathological and molecular features of medulloblastoma
 Genotypes for hTERT mutations: WT for both c.-124:G>A and c.-146:G>A mutations, c.-124:GA (heterozygous mutant), c.-124:AA (homozygous mu-
tant), c.-146:GA (heterozygous mutant) and c.-146:AA (homozygous mutant). Genotypes for hTERT rs2853669 SNP: AA (WT), AG (heterozygous mutant) 
and GG (homozygous mutant). – = Data not available; m = months; OS = overall survival.
a The same mutational status was seen in the primary and the recurrent sample of this case.
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 Discussion 
 Promoter mutations of the  hTERT gene were first de-
scribed in melanoma in 2 distinct reports  [13, 14] . Since 
then,  hTERT promoter mutations have been described 
across several tumor types, and are one of the most fre-
quent genetic alterations involved in human tumorigen-
esis  [12, 25] . 
 In this study, we demonstrate that 28% of our medul-
loblastoma samples presented  hTERT hotspot promoter 
mutations, in line with previous reports (18–33%)  [10, 11, 
25, 26] . These mutations were more frequent in older pa-
tients (p < 0.0001), were not seen in any infants (aged <4 
years) and were only present in 3 children of 12, 14 and 
16 years of age. Previous reports have shown the same 
trend, with Koelsche et al.  [26]  reporting 3 and 65% of 
these mutations, respectively, in pediatric and adult pa-
tients. This is line with the literature that demonstrates 
clinical and molecular characteristics distinguishing pe-
diatric and adult medulloblastomas  [27] .  hTERT muta-
tions have been described to be associated with less meta-
static medulloblastoma at diagnosis  [10] , and we have 
shown that these tumors were more prone to recurrence 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Fig. 1. Representative electropherogram traces of  hTERT Sanger sequencing from a WT sample and c.-124:G>A 
and c.-146:G>A mutant cases. Arrows indicate the mutated nucleotide. 
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 Fig. 2. Kaplan-Meier survival curves for  hTERT WT and mutant 
samples. No statistical differences were seen between the 2 groups 
(p = 0.200, log-rank test). 
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(p = 0.026) compared to the  hTERT WT medulloblasto-
mas. In addition, we also demonstrate, for the first time, 
that  hTERT mutations were significantly enriched in
tumors arising in the right cerebellar hemisphere (p = 
0.039).
 Mutations in histone 3 leading to K27M and G34R/
G34V have been extensively reported in pediatric high-
grade gliomas  [18, 19] . In spite of this, not many works 
have reported the results of these mutations in medullo-
blastomas. In 2014, Huether et al.  [20] studied >1,000 
different pediatric cancers, 70 of which were medullo-
blastomas, and did not see histone mutations in this 
brain tumor type. Similarly, we successfully sequenced 
approximately 60 samples for the hotspot mutations of 
 HIST1H3B and  H3F3A and found no mutations in our 
samples. Currently, it is well accepted that medulloblas-
tomas can be cytogenetically and molecularly stratified 
into distinct subgroups that are associated with distinct 
clinicopathological features  [28, 29] .  hTERT mutations 
have been reported more frequently in the SHH molecu-
lar subgroup  [10] , but further studies are needed to vali-
date whether they are associated with particular cytoge-
netic and molecular subtypes. 
 In conclusion, we reported that hotspot  hTERT muta-
tions are present in approximately 1/3 of medulloblasto-
mas cases and are associated with older patients and re-
current tumors, constituting a potential biomarker for 
medulloblastomas.
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 Table 2.  Association of hTERT mutation with clinicopathological 
features of medulloblastoma
Characteristic hTERT 
WT
hTERT 
mutation
p value
Age, years
Median 11 26 <0.0001a
Range 1.5 – 65 12 – 70
n.a. 1 1
Gender
Female 15 7 1.000c
Male 30 14
n.a. 2 1
Histology
Classic 38 14 0.108c
Desmoplastic 6 7
Anaplastic 0 0
Nodular 2 0
n.a. 1 1
Metastasis
Negative 16 9 0.286b
Positive 5 0
n.a. 26 13
Recurrence
Negative 18 8 0.026c
Positive 2 6
n.a. 27 8
Location 
Cerebellar vermis + 
4th ventricle 26 8 0.039b
Right cerebellar hemisphere 4 7
Left cerebellar hemisphere 4 3
n.a. 13 4
 a Mann-Whitney U test. b Fisher’s exact test. c χ2 test.
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